Triple Antithrombotic Therapy for the Prevention of Left Ventricular Thrombus Following Anterior ST-Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis.
Anastasios Apostolos, Vasileios Panoulas
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed prophylactic triple antithrombotic therapy (TAT) versus dual antiplatelet therapy (DAPT) for preventing left ventricular thrombus (LVT) in adults with anterior STEMI treated with primary PCI. Six studies including 2021 patients were pooled. TAT was not associated with a statistically significant reduction in LVT formation (RR: 0.54, 95% CI: 0.21-1.40; P = 0.21), while major bleeding was significantly increased (RR: 2.69, 95% CI: 1.40-5.19; P = 0.003). The authors conclude that these findings do not support routine prophylactic TAT in unselected patients.
Key findings
- TAT did not significantly reduce LVT formation versus DAPT (RR: 0.54, 95% CI: 0.21-1.40; P = 0.21; I 2 = 61%).
- Major bleeding was more frequent with TAT (RR: 2.69, 95% CI: 1.40-5.19; P = 0.003; I 2 = 14%).
- Systemic embolism showed a nonsignificant trend toward reduction with TAT (RR: 0.44, 95% CI: 0.18-1.07; P = 0.07; I 2 = 0%).
Why it matters
Preventing LVT after anterior STEMI must be balanced against the harms of adding anticoagulation to antiplatelet therapy. In this pooled evidence, a significant reduction in LVT was not demonstrated, whereas major bleeding increased. The results therefore highlight the importance of avoiding assumptions that prophylactic intensification provides net benefit across unselected patients.
What to keep in mind
The pooled estimate for LVT had substantial heterogeneity (I 2 = 61%), and the confidence interval does not exclude either benefit or no benefit. The abstract also notes that supporting evidence for prophylactic anticoagulation is of low certainty.